Mavyret (glecapravir, pibrentasvir) is a fixed dose combination drug used in the treatment of chronic hepatitis C (HCV) infection. The drugs used in Mavyret work by blocking two individual proteins that the virus needs to replicate. Mavyret was approved on August 3, 2017 by the U.S. Food and Drug Administration for...